Lakefront Biotherapeutics is a biotechnology company focused on developing medicines for patients with serious diseases, primarily in immunology and inflammation. The company operates as a single segment, leveraging deal-making expertise to identify, acquire, and advance clinical-stage assets. Its current pipeline is anchored by gamgertamig, a BCMAxCD3 T-cell engager for autoimmune diseases such as autoimmune hemolytic anemia and immune thrombocytopenia, which was acquired through the Ouro Medicines transaction. The company previously maintained a cell therapy portfolio including CAR-T candidates for oncology, but initiated the wind-down of these activities in early 2026 to refocus resources on strategic business development. Lakefront Biotherapeutics was formerly known as Galapagos NV, a name it used until April 2026, and was incorporated in 1999. The company collaborates with Gilead Sciences on next-generation T-cell engager therapies and has in-licensed additional preclinical autoimmune programs. Its business model prioritizes modality-agnostic asset selection and operational flexibility to build a differentiated clinical-stage portfolio.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage lakefrontbio.com
Sector Healthcare IR page lakefrontbio.com/investors
Tags
immunology, inflammation, t-cell engagers, autoimmune diseases, oncology, cell therapy, car-t, business development, asset acquisition, clinical-stage pipeline, gamgertamig, OM336, GLPG3667, GLPG5101, GLPG5301, Ouro Medicines, Gilead Sciences, CellPoint, AboundBio, Alfasigma, Jyseleca
Press page —

Metrics

Valuation  
Market cap € 1.954B
Market cap (USD) $ 2.143B
P/E 5.36
PEG —
P/BV 0.53
P/S 3.55
P/OCF -3.42
P/FCF -3.08
Dividend yield —
Turnover / mcap —
Returns  
ROE 10.5%
ROI 10.2%
ROIC 9.4%
Profit margin 28.8%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 68
Quality score 22.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 1.112B 275.649M 239.724M 505.28M 484.846M 478.053M 844.985M 288.836M 127.087M 129.519M — —
Net profit 320.884M 74.082M 211.697M -217.991M -103.231M -305.436M 149.845M -29.259M -115.704M 54.012M -118.41M 33.211M
Free cash flow -271.16M -336.746M -424.676M -527.933M -558.032M -469.858M 3.186B -152.858M -152.342M 234.945M — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 27.81 25.04 37.35 44.07 46.77 84.68 186.01 78.89 79.82 57.48 56.56 —
Price performance 12m 0.19 -0.32 -0.08 -0.19 -0.44 -0.52 1.25 -0.02 0.46 0.02 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Income detail
Research and development expense (EUR) 140M 219M 323M 427M 524M 492M 515M 241M 335M 459M
↳ 5y CAGR +32.2% +28.6% +18.7% -5.7% -4.7% -2.6%
Reported Mar 23, 2018 Mar 23, 2018 Mar 29, 2019 Mar 27, 2020 Mar 25, 2021 Mar 24, 2022 Mar 23, 2023 Mar 28, 2024 Mar 27, 2025 Mar 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Lakefront Creates New Subscription Right Plan Bull 0 Bear 1 Routine

Mechelen, Belgium; November 18, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) announced that its Board of Directors has created 150,000 subscription rights under a new subscription right plan on November 10, 2026.

On November 10, 2026, the Board of Directors of Lakefront approved the “Subscription Right Plan November 2026”, intended for personnel of the Company and its subsidiaries, within the framework of the authorized capital. Under this subscription right plan, 150,000 subscription rights were created for compensation of current and potential future employees. Each subscription right gives the right to subscribe to one new Lakefront share. More information can be found in the Board report published on the Lakefront website at Special reports | Lakefront Biotherapeutics (https://lakefrontbio.com/investors/corporate-governance/special-reports/).

Lakefront’s total share capital currently amounts to €356,444,938.61; the total number of securities conferring voting rights is 65,897,071, which is also the total number of shares (the “denominator”).

Mechelen, Belgium; November 16, 2026; 7.30 AM CET regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the initiation of a new share repurchase program of up to €50 million, following completion of its initial €50 million program announced on June 9, 2026.

Under the initial program, completed on October 16, 2026, Lakefront repurchased approximately 1.99 million ordinary shares for a total consideration of €50 million. The repurchased shares are held as treasury shares.

The new program will be carried out by Morgan Stanley & Co International PLC, acting as an independent financial intermediary under a discretionary mandate and making its trading decisions independently of Lakefront. Purchases will be made in the open market on Euronext under the terms and conditions approved by the Extraordinary Shareholders’ Meeting on April 28, 2026, and executed in accordance with industry best practices.

In accordance with the limits of the repurchase authorization granted, under the program, the Company may repurchase up to 4,604,550 ordinary shares for an aggregate amount of up to €50 million.

Mechelen, Belgium; November 10, 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the 2026 Jefferies Global Healthcare Conference in London at 2:00 pm GMT (9:00 am ET) on Tuesday, November 17, 2026.

A live webcast of the presentation will be accessible on the Investors page of the Company’s website at Webcasts & Events - Lakefront Biotherapeutics. A replay of the webcast will be available following the completion of the event and will be archived for up to 90 days.

About Lakefront Biotherapeutics

Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune diseases.

Prompts

Lakefront Biotherapeutics (ticker LKFT), listed in United States.

Company History

Date Change Detail
May 8, 2026 Renamed GALAPAGOS NV → Lakefront Biotherapeutics NV
— Former tickers GLPG

ETFs Holding Lakefront Biotherapeutics

ETF Weight in ETF Shares Market value As of
ESIM 0.11% 695 $ 19.079K Jul 31, 2026
AVDS 0.07% 7,605 $ 264.578K Nov 16, 2026
APIE 0.05% 19,649 $ 559.997K Aug 31, 2026
AVDE 0.01% 39,584 $ 1.377M Nov 16, 2026
CORO 0.01% 47,246 $ 1.623M Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
GLPG delisted Common share — NL euronext — —
LKFT canonical Common share — US nasdaq 29.65 USD 2026-09-30
LKFT Common share — NL euronext — —